Youzhong Zhang

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

The deubiquitinase PSMD14 accelerates cervical cancer progression, with thiolutin offering a novel therapeutic approach

Abnormal function of deubiquitination enzymes is implicated in cancer progression. However, the role of the 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) in cervical cancer development and its underlying mechanisms remain poorly understood. In our study, we evaluated t...